晶泰科技与渡树宣布达成60亿美元的AI药物发现合作里程碑-动脉网

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

CISION 等信源发布 2025-08-07 07:56



可切换为仅中文







Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases.

战略合作伙伴关系利用人工智能和机器人技术，为肿瘤学、免疫学、炎症、神经病学和代谢疾病等领域的新型疗法提供支持。

CAMBRIDGE, Mass.

马萨诸塞州剑桥市

，

Aug. 6, 2025

2025年8月6日

/PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced a transformative strategic collaboration with DoveTree Medicines, a biotechnology pioneer founded by renowned drug developer Dr.

/PRNewswire/ -- 晶泰科技（2228.HK），一家全球领先的人工智能（AI）与机器人技术整合应用于药物和材料发现的科技公司，宣布与生物技术先锋企业多维医药达成一项变革性的战略合作。多维医药由著名药物研发专家创立。

。

Gregory Verdine

格雷戈里·维尔丁

. The collaboration, worth up to

合作价值高达

$5.99 billion

59.9亿美元

, represents one of the largest commitments to date for AI- and robotics-driven pharmaceutical R&D.

，代表了迄今为止在人工智能和机器人驱动的药物研发领域最大的承诺之一。

Under the agreement, DoveTree gains exclusive global rights to develop and commercialize a portfolio of innovative therapeutics generated through the partnership. XtalPi has received an upfront payment of

根据协议，DoveTree 获得了通过合作开发和商业化一系列创新疗法的全球独家权利。XtalPi 已收到预付款。

$51 million

5100万美元

and is eligible for

并且有资格获得

$49 million

4900万美元

in additional near-term payments, plus development and commercial milestones, as well as tiered royalties totaling up to

此外还有近期付款，以及开发和商业里程碑，还有总计高达一定比例的分级特许权使用费

$5.89 billion

58.9亿美元

。

This collaboration merges XtalPi's integrated drug discovery capabilities with DoveTree's deep biological expertise in selecting and validating novel targets of high therapeutic potential. Together, the companies will focus on developing first-in-class candidates across oncology, immunology and inflammatory diseases, neurological disorders, and metabolic dysregulation with significant unmet needs.

此次合作融合了晶泰科技的综合药物发现能力与道树生物在选择和验证高治疗潜力新靶点方面的深厚生物学专业知识。两家公司将共同专注于开发在肿瘤学、免疫学和炎症性疾病、神经障碍以及存在显著未满足需求的代谢失调领域的首创候选药物。

The partnership will advance DoveTree's selected pipeline of projects targeting historically challenging mechanisms, with plans to expand joint R&D capabilities in emerging modalities like molecular glue..

该合作将推动DoveTree针对历史上具有挑战性机制的选定项目管道，并计划在分子胶等新兴领域拓展联合研发能力。

DoveTree Medicines was founded by Dr.

鸠树医药由博士创立。

Gregory Verdine

格雷戈里·维尔丁

, an internationally esteemed scientist, entrepreneur, and seasoned investor in the biopharmaceutical field, with outstanding achievements in both academia and industry. He has co-founded over a dozen biopharmaceutical companies, including more than five publicly listed firms such as Enanta Pharmaceuticals (NASDAQ: .

，国际知名科学家、企业家和生物制药领域的资深投资人，在学术界和工业界均取得了卓越的成就。他共同创立了十几家生物制药公司，其中五家以上为上市公司，例如Enanta Pharmaceuticals（纳斯达克代码：。

ENTA

), Rein Therapeutics (NASDAQ:

)，Rein Therapeutics（纳斯达克：

RNTX

), and WaVe Life Sciences (NASDAQ:

），以及WaVe生命科学（纳斯达克：

WVE

). Credited with originating the 'drugging the undruggable' concept, Dr. Verdine has pioneered unique molecular glue and peptide technology platforms, successfully applying them to the drug development against 'undruggable' proteins such as RAS, Myc, and β-catenin. He has co-developed three FDA-approved drugs, with over a dozen additional candidates currently in clinical development..

). 被认为是“让不可成药的靶点成药”这一概念的开创者，Verdine博士率先开发了独特的分子胶和多肽技术平台，并成功将其应用于针对RAS、Myc和β-catenin等“不可成药”蛋白的药物开发。他共同开发了三种FDA批准的药物，目前还有十几种候选药物正在临床开发中。

XtalPi has developed an intelligent de novo drug discovery platform that spans small molecules, biologics, antibody-drug conjugates (ADCs), and molecular glues. This multimodal capability enables the efficient exploration of parallel drug development approaches against single targets and unlocks broader chemical space.

晶泰科技开发了一个涵盖小分子、生物制品、抗体-药物偶联物（ADC）和分子胶的智能从头药物发现平台。这种多模式能力使得针对单一靶点的并行药物开发方法得以高效探索，并解锁了更广阔的化学空间。

By integrating quantum physics predictions, AI-driven molecular design, and a large-scale robotic lab-in-the-loop, XtalPi significantly accelerates the drug discovery workflow—from target analysis and molecular generation to affinity prediction, ADMET assessment, and synthesis design—with enhanced accuracy and efficiency.

通过整合量子物理预测、人工智能驱动的分子设计以及大规模机器人实验室循环，晶泰科技显著加速了药物发现工作流程——从靶点分析、分子生成到亲和力预测、ADMET评估和合成设计——同时提升了准确性和效率。

Through extensive partnerships with innovative pharmaceutical companies, XtalPi's platform has been rigorously validated in real-world projects, accumulating vast datasets of standardized experimental data and .

通过与创新型制药公司的广泛合作，XtalPi的平台在实际项目中得到了严格的验证，积累了大量标准化实验数据的数据集。

high-precision computational data

高精度计算数据

to continuously optimize models within a closed feedback loop.

在封闭的反馈回路中持续优化模型。

Dr.

博士

Gregory Verdine

格雷戈里·维尔丁

, Founder and Chief Executive Officer of DoveTree, stated: 'XtalPi's unique platform has the potential to transform the profound uncertainties of drug discovery into quantifiable engineering solutions. Their demonstrated ability to innovate at scale makes them a valuable partner in pursuing drug targets that are beyond conventional methods.

DoveTree创始人兼首席执行官表示：“XtalPi独特的平台有潜力将药物发现的深刻不确定性转化为可量化的工程解决方案。他们大规模创新的能力已得到验证，这使得他们在追求传统方法无法触及的药物靶点时成为宝贵的合作伙伴。”

By merging DoveTree's biological insights and extensive R&D expertise with XtalPi's powerful platform, we aim to deliver transformative therapies for patients globally.'.

通过将DoveTree的生物学见解和广泛的研发专业知识与XtalPi的强大平台相结合，我们旨在为全球患者提供变革性的治疗方法。

Dr.

博士

Shuhao Wen

温书豪

, Chairman of XtalPi, commented: 'Dr. Verdine and DoveTree bring exceptional biological acumen, business vision, and a proven track record of translational success, perfectly complementing our platform's strengths in high-throughput molecule generation, design, and validation. This partnership positions us to accelerate breakthroughs against complex diseases while expanding the frontiers of AI-driven drug discovery.

晶泰科技董事长评论道：“Verdine博士和DoveTree带来了卓越的生物学智慧、商业视野以及经过验证的转化成功记录，完美地补充了我们平台在高通量分子生成、设计和验证方面的优势。这一合作使我们能够加速针对复杂疾病的突破，同时拓展人工智能驱动药物发现的前沿领域。”

XtalPi remains committed to advancing our core technologies and working closely with leading innovators to help build diverse pipelines of impactful medicines.'.

晶泰科技仍致力于推进我们的核心技术，并与领先的创新者紧密合作，帮助构建多样化的有影响力的药物管道。

About DoveTree Medicines

关于DoveTree医药品

DoveTree Medicines is a biotech company dedicated to discovering first-in-class medicines for diseases with profound unmet medical needs. Founded and led by distinguished scientist-entrepreneur Dr.

白鸽树医药是一家生物技术公司，致力于为存在重大未满足医疗需求的疾病发现首创药物。该公司由杰出的科学家兼企业家创立并领导。

Gregory Verdine

格雷戈里·维尔丁

, DoveTree integrates deep biological insight and advanced AI to unlock novel therapeutic pathways and accelerate the development of transformative medicines, translating pioneering science into meaningful patient benefit.

，DoveTree整合了深入的生物学见解和先进的人工智能，以解锁新颖的治疗途径并加速变革性药物的开发，将开创性的科学转化为对患者有意义的利益。

About XtalPi

关于晶泰科技

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the

晶泰科技控股有限公司（晶泰科技，2228.HK）由三位物理学家于2015年创立，

Massachusetts Institute of Technology

麻省理工学院

(

MIT

麻省理工学院

). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries..

）。它是一个由量子物理、人工智能和机器人技术驱动的创新研发平台。通过整合第一性原理计算、人工智能算法、高性能云计算和标准化自动化系统，晶泰科技为制药、材料科学、农业科技、能源、新化学品和化妆品等行业的公司提供数字化和智能化的研发解决方案。

SOURCE XtalPi Inc.

来源：晶泰科技

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers